HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 8, 2009--
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen,
M.D., President & CEO, will present at the upcoming 2009 DB-Biotech
Boston Confab on Tuesday, December 15, 2009 at 2:05 p.m. ET at the Four
Seasons Hotel Boston in Boston, MA.
A live webcast of the presentation can be accessed under “Calendar of
Events” in the Acorda Investor Relations section of the website at www.acorda.com,
or you may use the link: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ACOR&item_id=2577018.
Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection. An archived version of the
webcast will be available until March 15, 2010 on the Acorda website in
the Investor Relations section; to access please use the link http://phoenix.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-irhome.
Acorda Therapeutics is a biotechnology company developing therapies for
spinal cord injury, multiple sclerosis and related nervous system
disorders. The Company's marketed products include Zanaflex Capsules®
(tizanidine hydrochloride), a short-acting drug for the management of
spasticity. The Company's pipeline includes a number of products in
development for the treatment, regeneration and repair of the spinal
cord and brain.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including delays in obtaining or failure to obtain FDA approval of
Fampridine-SR, the risk of unfavorable results from future studies of
Fampridine-SR, Acorda Therapeutics' ability to successfully market and
sell Fampridine-SR, if approved, and Zanaflex Capsules, competition,
failure to protect its intellectual property or to defend against the
intellectual property claims of others, the ability to obtain additional
financing to support Acorda Therapeutics' operations, and unfavorable
results from its preclinical programs. These and other risks are
described in greater detail in Acorda Therapeutics' filings with the
Securities and Exchange Commission. Acorda Therapeutics may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Acorda Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
Source: Acorda Therapeutics, Inc.
Jeff Macdonald, 914-347-4300 ext. 232